Entegrion Awarded $8.2 Million Department of Defense Contract

Sept. 10, 2010 - PRLog -- Research Triangle Park, NC -- The life sciences company Entegrion, Inc. announces receipt of a two-year $8.2 million research and development contract from the U.S. Department of Defense (DOD) for continuing development of a method for aseptic production of  dried human plasma for transfusion. This award follows a prior DOD contract for feasibility analysis and method development, which was completed earlier this year.

“We welcome the opportunity to continue development of this important capability for the Department of Defense. This technology will help improve the safety and availability of blood and blood products for transfusion in domestic and global health applications, and we are pleased to see the military’s continued confidence and investment commitment to the technology,” said Joseph A. DaCorta, Vice President and Chief Technology Officer for Entegrion. “The dried human plasma uses a technology that overcomes the normal limitation of shelf-life and refrigeration storage requirements of blood products. Such benefits are important to both civilian and military medical operations, especially in remote areas.”

John B. Mowell, Chairman of the Board, stated that the funds will be deployed to ‘scale-up’ production and to develop efficient manufacturing processes in support of the clinical development plan, scheduled to begin in 2011. Mowell added that he fully expects this critical phase of the dried plasma development work to pave the way for a successful launch of this important life-saving medical technology.

ABOUT ENTEGRION
Entegrion is a life sciences company that selectively integrates synergistic technologies with those in its patent portfolio for development of novel devices and drugs for hemorrhage control, resuscitation, and associated tissue repair. The company is based in North Carolina’s Research Triangle Park (RTP) and is the inventor of Stasilon®, an FDA-approved medical device technology that is in the form of a textile and is uniquely both hemostatic and non-adherent. Building on technologies licensed from the University of North Carolina, Entegrion’s portfolio includes platelet-derived platform technologies that are being developed as topical gels and sprays for tissue repair, infusible hemostatic agents for the control of internal hemorrhage, and novel vehicles for delivery of drugs to targeted tumors and other sites of internal bleeding. For more information, visit www.entegrion.com.